United States - English - NLM (National Library of Medicine)

sincerus florida llc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) -

United States - English - NLM (National Library of Medicine)

sincerus florida llc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) -

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

alimera sciences europe ltd. - fluocinolone acetonide 0,19 mg - intravitreal implant in applicator - 190 µg - fluocinolone acetonide 0.19 mg - fluocinolone acetonide

Canada - English - Health Canada

hill dermaceuticals inc - fluocinolone acetonide - emulsion - 0.01% - fluocinolone acetonide 0.01% - anti-inflammatory agents

Canada - English - Health Canada

bausch health, canada inc. - fluocinolone acetonide - solution - 0.01% - fluocinolone acetonide 0.01% - anti-inflammatory agents

Canada - English - Health Canada

bausch health, canada inc. - fluocinolone acetonide - ointment - 0.025% - fluocinolone acetonide 0.025% - anti-inflammatory agents

Canada - English - Health Canada

hill dermaceuticals inc - fluocinolone acetonide - solution - 0.01% - fluocinolone acetonide 0.01% - corticosteroids

Canada - English - Health Canada

bausch & lomb inc - fluocinolone acetonide - implant - 0.59mg - fluocinolone acetonide 0.59mg - corticosteroids

Canada - English - Health Canada

knight therapeutics inc. - fluocinolone acetonide - implant - 0.19mg - fluocinolone acetonide 0.19mg - corticosteroids

United States - English - NLM (National Library of Medicine)

eyepoint pharmaceuticals, inc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - yutiq ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. yutiq is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. yutiq is contraindicated in patients with known hypersensitivity to any components of this product. risk summary adequate and well-controlled studies with yutiq have not been conducted in pregnant women to inform drug associated risk. animal reproduction studies have not been conducted with yutiq. it is not known whether yutiq can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. yutiq should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary systemically administered corticosteroids are present in human milk and can suppress growth, interfere with endogenous corticosteroid production. clinical or nonclinical lactation studies have not been conducted with yutiq. it is not known whether intravitreal treatment with yutiq could result in sufficient systemic absorption to produce detectable quantities of fluocinolone acetonide in human milk, or affect breastfed infants or milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for yutiq and any potential adverse effects on the breastfed child from yutiq. safety and effectiveness of yutiq in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.